Oxford Global’s 13 th Annual Pharmaceutical IT Congress - Q&A Session

Oxford Global’s 13 th Annual Pharmaceutical IT Congress: A Q&A Session with Nigel Hughes, Director Integrative Healthcare Informatics, Janssen Pharma R&D and Marc Berger, Vice President, Real World Data and Analytics, Pfizer

Approaching our well-established 13th Annual Pharmaceutical IT Congress, we sat down with Nigel Hughes, Director Integrative Healthcare Informatics, Janssen Pharma R&D and Marc Berger, Vice President, Real World Data and Analytics, Pfizer, to talk about the pharmaceutical IT industry.

Nigel Hughes will be speaking on Day 2 of the 13th Annual Pharmaceutical IT Congress in the Novel Insights Into Translational Informatics stream: Good To Quickstep, But At Least We Should Tango:Data Collaborations Are A Dance And A Partnership. We asked Nigel…Collaborations are a key to success regarding data sharing. How do you think pharmaceutical companies could collaborate better in 2015?

“There are a number of initiatives that come into play here. First, within Europe for instance we have the IMI or Innovative Medicines Initiatives, EHR4CR or Electronic Health Records for Clinical Research is one, EMIF –the European Medical Information Framework, the GETREAL Initiative. These are just some examples where industry, EU funding, academia and clinical care are coming together to collaborate on wider European collaborations to access clinical data for use in research and development, market and business intelligence understanding and so forth. So those are initiatives that are kind of pre -competitive, and enable large numbers of companies to collaborate with lots of stakeholders across Europe. I think these are good examples of where things could be going in the future. Certainly, outside of those initiatives, it is probably a bit more challenging and the industry as a whole is slowly moving towards a model where companies can collaborate on large scale programs for data access. This is also coming from the market itself, from academia, from clinical centres and so forth, where if we look at areas like for instance oncology where there are increasing number of collaborations, in the United States, in Europe, and internationally between clinical centres, between clinical centres and pharmaceutical companies and so forth. What is not really happening is where other companies are collaborating together –and that remains a challenge in this competitive environment. So I think more of the same, where it is working, we need to do more in 2015 but certainly there is still a lot more to do in terms of bringing together all of these key stakeholders to the benefit of healthcare.”

Marc Berger will be speaking on Day 1 of the 13th Annual Pharmaceutical IT Congress in our Big Data Challenges stream: Big Data and Real World Data: How They Are Transforming Drug Development? We asked Mark…What does Real World Evidence in 2015 mean for Pfizer and in your opinion what future opportunities does it have in the pharmaceutical industry?

“There are many new sources of digitised real world data that are widely available now. We have had access to medical claims data for the last 30 years or more; recently we have gained access to Electronic Medical Record Data and many other novel kind of data including laboratory data, genomic and other ‘omic data, and sensor/wearable data. These new data sources offer the opportunity to gain insights into unmet medical needs:how patients are being treated, who might benefit most from new therapies, and how we can leverage that information to enhance the effectiveness  and  efficiency  of  both  drug  development  and commercialisation. As industry and regulatory bodies get more experience  with  these new data sources and methods continue to advance, there is a case to be made that indications should be supported with real world evidence and not only with randomized controlled trials.”

Want to read more?
To view the full Q&As visit: http://www.pharmatechnology-summit.com/who-is-speaking/qa/

Want to attend the 13 th Annual Pharmaceutical IT Congress?
Taking place on 23-24 September 2015 at The Royal College of Surgeons of England this congress will be attended by over 150 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions. Over 40 presentations and case studies focusing on the key developments in Big Data, Translational Informatics, Data Management and IT Solutions.

If you would like to be a part of this 2 day event please contact Danielle Dalby on
d.dalby@oxfordglobal.co.uk  or call +44(0)1865 248455.

Download the full conference programme here: http://www.pharmatechnology-summit.com/download-agenda-marketing/